Physician profile
Ofek Hai
NPI 1710111661
$726.00
in general payments reported to CMS, 2019-2025
11 companies · $361 in 2025
The $361 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.97 · 2022: $112 · 2023: $161 · 2024: $23.79 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $545.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $125.00 | 2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.62 | 2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $92.33 | 2025 | Assure Wcd |
| Boston Scientific Corporation | $81.41 | 2021-2022 | |
| Abbott Laboratories | $74.49 | 2022-2024 | Jot Dx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $72.88 | 2023-2025 | Lifevest |
| Pfizer INC. | $48.20 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $35.73 | 2025 | Eliquis, Camzyos |
| Irhythm Technologies, INC. | $28.67 | 2021 | |
| Amgen INC. | $25.83 | 2025 | Repatha |
| Chiesi USA, INC. | $20.84 | 2025 | Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ofek Hai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.